Abstract

Intuitive Surgical will report third-quarter results on October 20, 2026 Post-Mkt; this preview outlines consensus expectations for revenue, margins, net income, and adjusted EPS alongside business highlights and risk factors for the period.

Market Forecast

Consensus for the current quarter projects revenue at 2.91 billion US dollars, adjusted EPS at 2.64, and EBIT at 1.13 billion US dollars, implying year-over-year growth of 20.88% for revenue, 33.33% for EPS, and 35.41% for EBIT; details on gross margin and net margin are not guided but historically track in the high 60% and high 20% ranges, respectively. Intuitive Surgical’s core system and instruments/consumables franchises remain the primary drivers, with service recurring revenue providing resilience; the most promising growth vector is instruments and accessories revenue, with a growing installed base and higher utilization, which together support double-digit year-over-year expansion.

Last Quarter Review

In the previous quarter, revenue was 2.89 billion US dollars, gross margin was 67.78%, GAAP net profit attributable to the parent company was 818.00 million US dollars with a net margin of 28.29%, and adjusted EPS was 2.80, reflecting a 18.54% year-over-year revenue increase and a 27.85% rise in adjusted EPS. One notable highlight was operating leverage as EBIT reached 1.22 billion US dollars, outpacing revenue growth; by business line, products generated 2.42 billion US dollars and services contributed 472.40 million US dollars, with products representing roughly 83.67% of revenue and services 16.33%.

Current Quarter Outlook

Main business momentum and revenue composition

Intuitive Surgical’s revenue base is predominantly products revenue that captures da Vinci system placements and instruments and accessories. Instruments and accessories scale with procedure growth and utilization of the installed base, while system placements drive future recurring revenue. The company’s service line provides maintenance and digital support tied to installed systems, adding stability and visibility to cash flows. With the prior-quarter mix at roughly 83.67% products and 16.33% services, the near-term trajectory should continue to lean on procedure growth and utilization gains.

Most promising business vector

Instruments and accessories remain the most attractive growth engine given their direct linkage to procedure volumes. As hospitals expand robotic programs across general surgery, urology, and gynecology, utilization increases lift recurring instruments pull-through. This category benefits from higher-margin characteristics and predictable ordering patterns, which can expand gross margin when mix shifts favor consumables. The segments’ scalability, combined with an enlarging installed base of da Vinci systems, positions it for sustained double-digit year-over-year growth off the recent products revenue of 2.42 billion US dollars.

Key stock-price drivers this quarter

Investors are focused on three levers: procedure growth versus tough comparables, capital placements for new systems, and operating leverage. If procedure growth remains solid, instruments and accessories revenue should outperform, supporting EPS upside. System placements can be sensitive to hospital capital budgets and macro constraints; any broad-based hesitancy in capital spending could temper system revenue but would not derail the recurring instruments stream. On costs, scaling and productivity improvements can bolster margins, although currency and component costs could introduce variability; monitoring EBIT-to-revenue flow-through is crucial for assessing whether high 60% gross margins can translate into net margin expansion.

Analyst Opinions

Recent commentary skews bullish, with the majority of analysts expecting Intuitive Surgical to deliver revenue around the 2.91 billion US dollars mark and adjusted EPS near 2.64, supported by robust procedure growth and continued expansion of the installed base; price targets generally imply moderate upside into the print. Several well-known institutions emphasize utilization strength and resilience of the instruments and accessories stream as a buffer against potential variability in system placements. The prevailing view highlights that improving operating leverage, evidenced by the prior quarter’s EBIT outperformance relative to revenue growth, increases the likelihood of an EPS beat if procedure trends hold, though a minority cautions that hospital capital spending cycles could add volatility around system placements.